These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18627621)

  • 21. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
    Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
    J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
    Naymagon L; Abdul-Hay M
    J Med Case Rep; 2019 May; 13(1):153. PubMed ID: 31113466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Unusual Presentation of Multiple Myeloma: A 71-Year-Old Female With a Single Lytic Lesion of Her Appendicular Skeleton.
    Khalyfa A; Carrillo AC; Chavis Y
    Cureus; 2022 May; 14(5):e24725. PubMed ID: 35673306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Unusual Cause of Altered Mental Status in Multiple Myeloma: An Extraosseous Manifestation.
    Jaruvongvanich V; Spanuchart I; O-Charoen P; Kitamura C; Sumida L; Roytman M
    Hawaii J Med Public Health; 2016 Apr; 75(4):109-12. PubMed ID: 27099806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Grannis CH; Dewan VN; Wang RC
    Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lenalidomide in the treatment of multiple myeloma].
    Machálková K; Maisnar V
    Klin Onkol; 2009; 22(3):117-20. PubMed ID: 19708546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
    Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
    Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of lenalidomide in the treatment of multiple myeloma].
    Holánek M; Hájek R
    Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis].
    Kida M; Hirao M; Iizuka H; Hangaishi A; Usuki K
    Rinsho Ketsueki; 2016; 57(11):2339-2344. PubMed ID: 27941283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?
    Kreiniz N; Khateeb A; Gino-Moor S; Polliack A; Tadmor T
    Anticancer Res; 2016 Jun; 36(6):2889-92. PubMed ID: 27272801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan.
    Huang SY; Yu YB; Yeh SP; Chen TY; Kao WY; Chen CC; Wang MC; Lin HY; Lin SF; Lin TH; Hua Y; Puccio-Pick M; DeMarco D; Jacques C; Dunn P
    J Formos Med Assoc; 2017 Sep; 116(9):705-710. PubMed ID: 28012677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation.
    Miller WL; Mullan BP
    JACC Heart Fail; 2014 Jun; 2(3):298-305. PubMed ID: 24952698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.